Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP Michael Crowley sold 1,089 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $333.08, for a total transaction of $362,724.12. Following the transaction, the executive vice president now owns 2,011 shares of the company’s stock, valued at $669,823.88. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of NYSE BIO traded down $4.18 during midday trading on Friday, reaching $335.30. 96,694 shares of the stock were exchanged, compared to its average volume of 202,025. The company has a market capitalization of $9.99 billion, a P/E ratio of 57.41, a P/E/G ratio of 3.11 and a beta of 1.18. Bio-Rad Laboratories, Inc. has a 52-week low of $220.05 and a 52-week high of $345.50. The company has a current ratio of 4.68, a quick ratio of 3.36 and a debt-to-equity ratio of 0.11. The stock has a 50 day moving average price of $327.47 and a 200-day moving average price of $307.45.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, August 1st. The medical research company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.18. The business had revenue of $572.60 million during the quarter, compared to the consensus estimate of $564.88 million. Bio-Rad Laboratories had a net margin of 39.32% and a return on equity of 3.92%. The company’s quarterly revenue was down .6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.64 earnings per share. On average, analysts forecast that Bio-Rad Laboratories, Inc. will post 7.19 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. grew its holdings in shares of Bio-Rad Laboratories by 1.2% during the second quarter. BlackRock Inc. now owns 1,950,805 shares of the medical research company’s stock worth $609,803,000 after buying an additional 22,263 shares in the last quarter. American Century Companies Inc. grew its holdings in Bio-Rad Laboratories by 14.7% in the first quarter. American Century Companies Inc. now owns 788,955 shares of the medical research company’s stock valued at $241,168,000 after purchasing an additional 100,850 shares during the period. Atlanta Capital Management Co. L L C grew its holdings in Bio-Rad Laboratories by 0.7% in the second quarter. Atlanta Capital Management Co. L L C now owns 755,635 shares of the medical research company’s stock valued at $236,204,000 after purchasing an additional 5,522 shares during the period. Russell Investments Group Ltd. grew its holdings in Bio-Rad Laboratories by 3.9% in the second quarter. Russell Investments Group Ltd. now owns 411,262 shares of the medical research company’s stock valued at $128,208,000 after purchasing an additional 15,486 shares during the period. Finally, UBS Asset Management Americas Inc. grew its holdings in Bio-Rad Laboratories by 2.7% in the second quarter. UBS Asset Management Americas Inc. now owns 397,224 shares of the medical research company’s stock valued at $124,168,000 after purchasing an additional 10,536 shares during the period. Institutional investors and hedge funds own 61.95% of the company’s stock.

A number of brokerages have recently commented on BIO. Barclays lifted their price target on shares of Bio-Rad Laboratories from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. They noted that the move was a valuation call. Goldman Sachs Group upgraded shares of Bio-Rad Laboratories from a “buy” rating to a “conviction-buy” rating and set a $400.00 price target for the company in a report on Tuesday, August 20th. ValuEngine upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, August 2nd. Finally, Deutsche Bank lifted their price target on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a report on Thursday, May 9th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Bio-Rad Laboratories currently has an average rating of “Buy” and an average price target of $378.33.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Read More: How Investors Can Profit from Options Trading

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.